Photo by kostiantynvierkieiev from unsplash
Trastuzumab emtansine is an antibody–drug conjugate that is effective in human epidermal growth factor receptor-2 expressing advanced breast cancer. Trastuzumab emtansine is generally well tolerated and grade 3–4 toxicities are… Click to show full abstract
Trastuzumab emtansine is an antibody–drug conjugate that is effective in human epidermal growth factor receptor-2 expressing advanced breast cancer. Trastuzumab emtansine is generally well tolerated and grade 3–4 toxicities are rare. Pulmonary complications were rarely reported. Here we present a patient presenting with dyspnea after trastuzumab emtansine therapy and treated with a diagnosis of interstitial pneumonitis.
Keywords:
pneumonitis associated;
trastuzumab emtansine;
associated trastuzumab;
interstitial pneumonitis
Journal Title: Journal of Oncology Pharmacy Practice
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Oncology Pharmacy Practice
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!